Evidence map›Paper›PMID 38931887›Full record

ArticlePharmaceutics2024

Nanoliposomes Permeability in a Microfluidic Drug Delivery Platform across a 3D Hydrogel.

Corentin Peyret, Aleka Manousaki, Sabine Bouguet-Bonnet, Emmanuel Stratakis, Laura Sanchez-Gonzalez, Cyril J F Kahn, Elmira Arab-Tehrany

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Corentin PeyretUniversité de Lorraine, LIBio, F-54000 Nancy, France.ORCID 0009-0004-7860-1321
Aleka ManousakiInstitute of Electronic Structure and Laser (IESL), Foundation for Research and Technology Hellas (FORTH), 711 10 Heraklion, Greece.
Sabine Bouguet-BonnetUniversité de Lorraine, CNRS, CRM2, F-54000 Nancy, France.ORCID 0000-0001-7888-6487
Emmanuel StratakisInstitute of Electronic Structure and Laser (IESL), Foundation for Research and Technology Hellas (FORTH), 711 10 Heraklion, Greece.ORCID 0000-0002-1908-8618
Laura Sanchez-GonzalezUniversité de Lorraine, LIBio, F-54000 Nancy, France.
Cyril J F KahnUniversité de Lorraine, LIBio, F-54000 Nancy, France.ORCID 0000-0001-5282-6558
Elmira Arab-TehranyUniversité de Lorraine, LIBio, F-54000 Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoliposomes are nano-sized vesicles that can be used as drug delivery carriers with the ability to encapsulate both hydrophobic and hydrophilic compounds. Moreover, their lipid compositions facilitate their internalization by cells. However, the interaction between nanoliposomes and the membrane barrier of the human body is not well-known. If cellular tests and animal testing offer a solution, their lack of physiological relevance and ethical concerns make them unsuitable to properly mimic human body complexity. Microfluidics, which allows the environment of the human body to be imitated in a controlled way, can fulfil this role. However, existing models are missing the presence of something that would mimic a basal membrane, often consisting of a simple cell layer on a polymer membrane. In this study, we investigated the diffusion of nanoliposomes in a microfluidic system and found the optimal parameters to maximize their diffusion. Then, we incorporated a custom made GelMA with a controlled degree of substitution and studied the passage of fluorescently labeled nanoliposomes through this barrier. Our results show that highly substituted GelMA was more porous than lower substitution GelMA. Overall, our work lays the foundation for the incorporation of a hydrogel mimicking a basal membrane on a drug delivery microfluidic platform.

Indexed as

apparent permeabilitygelatin methacryloylmembrane barriermicrofluidicnanoliposomesporosity

Identifiers

PMID38931887
PMCPMC11207390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.